Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations

Pokaż inne wersje (1)

Molecular genetic assays for the detection of the JAK2 V617F (c.1849G>T) and other pathogenetic mutations within JAK2 exon 12 and MPL exon 10 are part of the routine diagnostic workup for patients presenting with erythrocytosis, thrombocytosis or otherwise suspected to have a myeloproliferati...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Bench, A, White, H, Foroni, L, Godfrey, A, Gerrard, G, Akiki, S, Awan, A, Carter, I, Goday-Fernandez, A, Langabeer, SE, Clench, T, Clark, J, Evans, P, Grimwade, D, Schuh, A, McMullin, M, Green, A, Harrison, C, Cross, N
Format:	Journal article
Wydane:	2013

Podobne zapisy

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.
od: Bench, A, i wsp.
Wydane: (2013)

The JAK2V617F mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden
od: Lai Yee Orbell, i wsp.
Wydane: (2023-11-01)

Modification of the histone landscape with JAK inhibition in myeloproliferative neoplasms
od: Greenfield, G, i wsp.
Wydane: (2020)

Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms – long term follow-up of a regional case series
od: Graeme Greenfield, i wsp.
Wydane: (2018-12-01)

JAK2 V617F Analysis in Indonesian Myeloproliferative Neoplasms Patients
od: Fanti Saktini, i wsp.
Wydane: (2015-12-01)

Epigenetics in myeloproliferative neoplasms
od: Graeme Greenfield, i wsp.
Wydane: (2023-07-01)

Evaluation of JAK2V617F Mutation Prevalence in Myeloproliferative Neoplasm by AS-RT-PCR
od: B Bahar, i wsp.
Wydane: (2009-11-01)

Evaluation of JAK2V617F mutation prevalence in Myeloproliferative Neoplasm by AS-RT-PCR
od: H Ghafari, i wsp.
Wydane: (2009-09-01)

Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms
od: Koki Ueda, i wsp.
Wydane: (2017-06-01)

Analysis of JAK2 V617F mutation in Tunisian patients with myeloproliferative neoplasms
od: Soumaya Chadi, i wsp.
Wydane: (2021-04-01)

Myeloproliferative neoplasms
od: Nick Cross, (Coordinating Author)
Wydane: (2019-06-01)

Evaluation of JAK2V617F mutation patients with non-CML myeloproliferative neoplasms by ARMS-PCR
od: F Nadali, i wsp.
Wydane: (2008-12-01)

Evaluation of JAK2V617F Mutation Patients with Non-CML Myeloproliferative Neoplasms by ARMS-PCR
od: K Alimoghaddam, i wsp.
Wydane: (2008-09-01)

Molecular pathogenesis of the myeloproliferative neoplasms
od: Graeme Greenfield, i wsp.
Wydane: (2021-06-01)

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms
od: Yonal-Hindilerden I, i wsp.
Wydane: (2015-06-01)

The JAK2 V617F Mutation in Plasma Cell Neoplasms with Co-existing Erythrocytosis
od: Stephen E. Langabeer
Wydane: (2015-12-01)

JAK out of the box: myeloproliferative neoplasms--associated JAK2 V617F mutations contribute to aortic aneurysms
od: Shannon Elisabeth Elf
Wydane: (2021-02-01)

Adrenal infarction with latent myelodysplastic/myeloproliferative neoplasm, unclassifiable with JAK2V617F mutation
od: Shunichiro Yasuda, i wsp.
Wydane: (2024-04-01)

Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms
od: Panhong Gou, i wsp.
Wydane: (2024-01-01)

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms
od: İpek Yonal Hindilerden, i wsp.
Wydane: (2023-08-01)

Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance
od: Saeid Shahrabi, i wsp.
Wydane: (2018-10-01)

PB2040: INTERRELATION BETWEEN JAK2 V617F MUTATION AND THE INCIDENCE OF THROMBOTIC EVENTS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
od: D. Nikolova, i wsp.
Wydane: (2022-06-01)

Protracted Clonal Trajectory of a JAK2 V617F-Positive Myeloproliferative Neoplasm Developing during Long-Term Remission from Acute Myeloid Leukemia
od: Stephen E. Langabeer, i wsp.
Wydane: (2018-01-01)

JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate
od: Camilla Nielsen, i wsp.
Wydane: (2014-09-01)

P1046: SEVERE COMPLICATIONS IN JAK2 V617F POSITIVE PEDIATRIC PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
od: W. Novak, i wsp.
Wydane: (2022-06-01)

Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms
od: Kristin Holl, i wsp.
Wydane: (2024-02-01)

Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm
od: Fani Kalala, i wsp.
Wydane: (2012-06-01)

Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm
od: Kasper Mønsted Pedersen, i wsp.
Wydane: (2020-05-01)

Soluble interleukin-6 receptor in patients with JAK2V617F somatic mutation and myeloproliferative neoplasm
od: Christoph Garbers, i wsp.
Wydane: (2020-05-01)

Myeloproliferative Neoplasms Associated with Mutation in JAK2V617F and Tyrosine Kinase Inhibitors as Therapeutic Strategy
od: Kaveh Tari, i wsp.
Wydane: (2015-04-01)

Allelic expression imbalance of JAK2 V617F mutation in BCR-ABL negative myeloproliferative neoplasms.
od: Hye-Ran Kim, i wsp.
Wydane: (2013-01-01)

Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis
od: Alexandre Guy, i wsp.
Wydane: (2020-06-01)

Evaluation of the JAK2V617F mutational burden in patients with philadelphia chromosome negative myeloproliferative neoplasms: A single-center experience
od: Popova-Labachevska M, i wsp.
Wydane: (2019-12-01)

SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases
od: Joanne Elliott, i wsp.
Wydane: (2009-04-01)

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
od: Shirin Ferdowsi, i wsp.
Wydane: (2016-04-01)

SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm
od: Yue Yang, i wsp.
Wydane: (2023-11-01)

Differential modulation of mutant CALR and JAK2 V617F-driven oncogenesis by HLA genotype in myeloproliferative neoplasms
od: Velizar Shivarov, i wsp.
Wydane: (2024-09-01)

PB2193: JAK2 V617F MUTATION BURDEN DETECTION AND RELATIONSHIP WITH LABORATORY CHARACTERISTICS IN MYELOPROLIFERATIVE NEOPLASMS
od: Xuefei MA, i wsp.
Wydane: (2023-08-01)

Coexistence of JAK2V617F and CALR mutation in Tunisian cohort with Philadelphia-negative chronic myeloproliferative neoplasms
od: Hejer Elmahmoudi, i wsp.
Wydane: (2023-01-01)

JAK2 V617F-dependent upregulation of PU.1 expression in the peripheral blood of myeloproliferative neoplasm patients.
od: Tamotsu Irino, i wsp.
Wydane: (2011-01-01)